VivoSeq
Other

Hyperbaric Bupivacaine

0

Pipeline Programs

5

Active Trials

0

Companies Involved

Hyperbaric Bupivacaine is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

5/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

22

clinical trials

Completed13 · 59%
Unknown status3 · 14%
Not yet recruiting2 · 9%
Active, not recruiting2 · 9%
Withdrawn1 · 5%
Recruiting1 · 5%

Trial Activity

22 trials

Hyperbaric Bupivacaine and Hyperbaric Levobupivacaine in C/S
Completed··Phase 4·NCT02025374·60 enrolled
Sequential and Mixture Injection of Opioids and Hyperbaric Bupivacaine
Completed··Phase 4·NCT04403724·126 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)